JP7589997B2 - 遺伝子の発現のための変異体リバーステトラサイクリントランスアクチベーター - Google Patents
遺伝子の発現のための変異体リバーステトラサイクリントランスアクチベーター Download PDFInfo
- Publication number
- JP7589997B2 JP7589997B2 JP2021517702A JP2021517702A JP7589997B2 JP 7589997 B2 JP7589997 B2 JP 7589997B2 JP 2021517702 A JP2021517702 A JP 2021517702A JP 2021517702 A JP2021517702 A JP 2021517702A JP 7589997 B2 JP7589997 B2 JP 7589997B2
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- sequence
- seq
- promoter
- engineered nucleic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
- A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/635—Externally inducible repressor mediated regulation of gene expression, e.g. tetR inducible by tetracyline
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/001—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination
- C12N2830/002—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor
- C12N2830/003—Vector systems having a special element relevant for transcription controllable enhancer/promoter combination inducible enhancer/promoter combination, e.g. hypoxia, iron, transcription factor tet inducible
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Virology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862738894P | 2018-09-28 | 2018-09-28 | |
| US62/738,894 | 2018-09-28 | ||
| PCT/US2019/053492 WO2020069339A1 (en) | 2018-09-28 | 2019-09-27 | Mutant reverse tetracycline transactivators for expression of genes |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022501060A JP2022501060A (ja) | 2022-01-06 |
| JP2022501060A5 JP2022501060A5 (cg-RX-API-DMAC7.html) | 2022-10-05 |
| JP7589997B2 true JP7589997B2 (ja) | 2024-11-26 |
Family
ID=68242854
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021517702A Active JP7589997B2 (ja) | 2018-09-28 | 2019-09-27 | 遺伝子の発現のための変異体リバーステトラサイクリントランスアクチベーター |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US12624362B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3856260A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7589997B2 (cg-RX-API-DMAC7.html) |
| CN (1) | CN113164625B (cg-RX-API-DMAC7.html) |
| CA (1) | CA3113470A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020069339A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12274733B2 (en) | 2018-09-28 | 2025-04-15 | President And Fellows Of Harvard College | Cellular reprogramming to reverse aging and promote organ and tissue regeneration |
| WO2020069373A1 (en) * | 2018-09-28 | 2020-04-02 | President And Fellows Of Harvard College | Cellular reprogramming to reverse aging and promote organ and tissue regeneration |
| WO2020069339A1 (en) | 2018-09-28 | 2020-04-02 | President And Fellows Of Harvard College | Mutant reverse tetracycline transactivators for expression of genes |
| IL292740A (en) * | 2019-11-05 | 2022-07-01 | Lonza Walkersville Inc | Allogeneic t cells and methods for their production |
| GB202103327D0 (en) * | 2021-03-10 | 2021-04-21 | Babraham Inst | Novel method |
| US12467917B2 (en) | 2021-03-16 | 2025-11-11 | California Institute Of Technology | Reconstructing human early embryogenesis in vitro with pluripotent stem cells |
| US20240384277A1 (en) * | 2021-06-15 | 2024-11-21 | Modernatx, Inc. | Engineered polynucleotides for cell-type or microenvironment-specific expression |
| CN118510886A (zh) | 2021-12-14 | 2024-08-16 | 加州理工学院 | 用于从干细胞体外生成胚胎的方法、培养基和装置 |
| WO2023196851A1 (en) * | 2022-04-06 | 2023-10-12 | President And Fellows Of Harvard College | Reversing aging of the central nervous system |
| WO2024012504A1 (zh) * | 2022-07-12 | 2024-01-18 | 南京瑞初医药有限公司 | 组合物及其使用方法 |
| EP4562163A1 (en) * | 2022-07-26 | 2025-06-04 | ModernaTX, Inc. | Engineered polynucleotides for temporal control of expression |
| CN116004789B (zh) * | 2022-08-01 | 2024-06-04 | 湖南家辉生物技术有限公司 | 一种Seckel综合征致病基因CEP152突变位点的应用及其诊断试剂 |
| US12252518B2 (en) | 2023-01-06 | 2025-03-18 | Life Biosciences, Inc. | Methods of treating non-arteritic anterior ischemic optic neuropathy |
| WO2026149568A1 (zh) * | 2025-01-10 | 2026-07-16 | 健达九州(北京)生物科技有限公司 | 基因构建体及其用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014500022A (ja) | 2010-11-24 | 2014-01-09 | クロンテック・ラボラトリーズ・インコーポレーテッド | 分散型タンパク質形質導入ドメインを含む誘導性発現系転写モジュレータおよびその使用方法 |
| WO2014152607A2 (en) | 2013-03-14 | 2014-09-25 | University Of Massachusetts | Dosage compensating transgenes and cells |
Family Cites Families (139)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
| US5589362A (en) | 1993-06-14 | 1996-12-31 | Basf Aktiengesellschaft | Tetracycline regulated transcriptional modulators with altered DNA binding specificities |
| EP0705334A1 (en) | 1993-06-14 | 1996-04-10 | Basf Aktiengesellschaft | Tight control of gene expression in eucaryotic cells by tetracycline-responsive promoters |
| US5543158A (en) | 1993-07-23 | 1996-08-06 | Massachusetts Institute Of Technology | Biodegradable injectable nanoparticles |
| US5741516A (en) | 1994-06-20 | 1998-04-21 | Inex Pharmaceuticals Corporation | Sphingosomes for enhanced drug delivery |
| AU746850B2 (en) | 1994-07-01 | 2002-05-02 | Tet Systems Holding Gmbh & Co. Kg | Tetracycline-regulated transcriptional modulaters |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| IE80468B1 (en) | 1995-04-04 | 1998-07-29 | Elan Corp Plc | Controlled release biodegradable nanoparticles containing insulin |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US5928941A (en) | 1996-10-07 | 1999-07-27 | President And Fellows Of Harvard College | Repressor kruppel-like factor |
| DE19818620A1 (de) | 1998-04-21 | 1999-10-28 | Metagen Gesellschaft Fuer Genomforschung Mbh | Menschliche Nukleinsäuresequenzen aus Blase-Normal |
| DE19851415B4 (de) | 1998-11-07 | 2010-11-04 | Wolfgang Hillen | Mutanter Transaktivator |
| US20080050393A1 (en) | 1998-12-03 | 2008-02-28 | Tang Y Tom | Novel nucleic acids and polypeptides |
| WO2000069450A1 (en) | 1999-05-19 | 2000-11-23 | The Uab Research Foundation | Oncogene identification by transformation of rk3e cells and uses thereof |
| US20030138799A1 (en) | 1999-05-19 | 2003-07-24 | Ruppert J. Michael | Oncogene identification by transformation of RK3E cells and uses thereof |
| US7364868B2 (en) | 1999-05-19 | 2008-04-29 | The Uab Research Foundation | Krüppel-like transcriptional factor KLF4/GKLF and uses thereof |
| ATE458818T1 (de) | 1999-06-07 | 2010-03-15 | Tet Systems Holding Gmbh & Co | Tet repressor basierte transkriptionale regulatorische proteine |
| US20110171185A1 (en) | 1999-06-30 | 2011-07-14 | Klimanskaya Irina V | Genetically intact induced pluripotent cells or transdifferentiated cells and methods for the production thereof |
| AU2001234944A1 (en) | 2000-02-03 | 2001-08-14 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
| US20070042392A1 (en) | 2000-02-03 | 2007-02-22 | Nuvelo, Inc. | Novel nucleic acids and polypeptides |
| US20030165921A1 (en) | 2000-02-03 | 2003-09-04 | Tang Y. Tom | Novel nucleic acids and polypeptides |
| US20050064454A1 (en) | 2000-06-05 | 2005-03-24 | Young Paul E. | Cancer gene determination and therapeutic screening using signature gene sets |
| US20020165180A1 (en) | 2000-09-18 | 2002-11-07 | Zoe Weaver | Process for identifying anti-cancer therapeutic agents using cancer gene sets |
| AU2001264559A1 (en) | 2000-06-05 | 2001-12-17 | Avalon Pharmaceuticals | Cancer gene determination and therapeutic screening using signature gene sets |
| US6750015B2 (en) | 2000-06-28 | 2004-06-15 | Kathryn B. Horwitz | Progesterone receptor-regulated gene expression and methods related thereto |
| US20030065157A1 (en) | 2001-04-04 | 2003-04-03 | Lasek Amy W. | Genes expressed in lung cancer |
| US20070060743A1 (en) | 2001-05-16 | 2007-03-15 | Tang Y Tom | Novel nucleic acids and polypeptides |
| WO2003012113A2 (en) | 2001-08-02 | 2003-02-13 | Gencell S.A. | Inducible expression systems employing ppar transcriptional activators |
| CN103589692B (zh) | 2001-11-13 | 2018-07-24 | 宾夕法尼亚大学托管会 | 检测和/或鉴定腺伴随病毒(aav)序列以及分离所鉴定的新型序列的方法 |
| US20030186281A1 (en) | 2001-12-21 | 2003-10-02 | Wolfgang Hillen | Modified tetracycline repressor protein compositions and methods of use |
| JP2004121218A (ja) | 2002-08-06 | 2004-04-22 | Jenokkusu Soyaku Kenkyusho:Kk | 気管支喘息または慢性閉塞性肺疾患の検査方法 |
| AU2003303144A1 (en) | 2002-10-18 | 2004-07-29 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| AU2003284357A1 (en) | 2002-11-01 | 2004-06-07 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| EP1572116A4 (en) | 2002-11-26 | 2007-12-12 | Genentech Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNE DISEASES |
| US20040219579A1 (en) | 2003-02-19 | 2004-11-04 | Natasha Aziz | Methods of diagnosis of cancer, compositions and methods of screening for modulators of cancer |
| GB0327384D0 (en) | 2003-11-25 | 2003-12-31 | Queen Mary & Westfield College | Gene therapy |
| US7682828B2 (en) | 2003-11-26 | 2010-03-23 | Whitehead Institute For Biomedical Research | Methods for reprogramming somatic cells |
| US20070072175A1 (en) | 2005-05-13 | 2007-03-29 | Biogen Idec Ma Inc. | Nucleotide array containing polynucleotide probes complementary to, or fragments of, cynomolgus monkey genes and the use thereof |
| EP1888627A2 (en) | 2005-05-20 | 2008-02-20 | Nederlands Instituut voor Hersenonderzoek | Nucleic acids and polypeptides that are useful in controlling neuronal regeneration |
| US20100190250A1 (en) | 2005-10-14 | 2010-07-29 | Jifan Hu | Methods of Rejuvenating Cells In Vitro and In Vivo |
| CA2630348C (en) | 2005-11-17 | 2016-01-12 | Stichting Voor De Technische Wetenschappen | Inducible expression systems |
| USRE49583E1 (en) | 2005-11-17 | 2023-07-18 | Tet Systems Gmbh & Co. Kg | Inducible expression systems |
| WO2007078599A2 (en) | 2005-12-16 | 2007-07-12 | The Board Of Trustees Of The Leland Stanford Junior University | Functional arrays for high throughput characterization of gene expression regulatory elements |
| US20070161031A1 (en) | 2005-12-16 | 2007-07-12 | The Board Of Trustees Of The Leland Stanford Junior University | Functional arrays for high throughput characterization of gene expression regulatory elements |
| WO2008051854A2 (en) * | 2006-10-20 | 2008-05-02 | Trustees Of Boston University | A tunable genetic switch for regulating gene expression |
| US8080647B2 (en) * | 2006-11-22 | 2011-12-20 | Pioneer Hi Bred International Inc | Tetracycline repressor and uses thereof |
| EP2126135A2 (en) | 2006-12-29 | 2009-12-02 | Tel HaShomer Medical Research Infrastructure and Services Ltd. | Methods and kits for predicting prognosis of multiple sclerosis |
| US9243226B2 (en) | 2007-02-23 | 2016-01-26 | University Of Central Florida Research Foundation, Inc. | Biasing of cells toward retinal, corneal or lens development |
| WO2008105630A1 (en) | 2007-02-27 | 2008-09-04 | Procell Therapeutics Inc. | Combined use of cell permeable nanog and oct4 for increasing self-renewal and suppressing differentiation of stem cells |
| WO2009028945A2 (en) | 2007-08-30 | 2009-03-05 | Academisch Ziekenhuis Bij De Universiteit Van Amsterdam | Pathways involved in arteriogenesis and uses thereof |
| AU2008297024B2 (en) | 2007-10-31 | 2014-08-28 | Kyoto University | Nuclear reprogramming method |
| US20110151447A1 (en) | 2007-11-06 | 2011-06-23 | Children's Medical Center Corporation | Method to produce induced pluripotent stem (ips) cells from non-embryonic human cells |
| US9005966B2 (en) | 2007-11-19 | 2015-04-14 | The Regents Of The University Of California | Generation of pluripotent cells from fibroblasts |
| EP2227241A1 (en) | 2007-11-30 | 2010-09-15 | Cytomatrix PTY LTD | Methods of inducing pluripotency involving sox2 protein |
| AU2008329563A1 (en) | 2007-11-30 | 2009-06-04 | Cytomatrix Pty Ltd | Methods of inducing pluripotency involving Oct4 protein |
| EP2268796A1 (en) | 2008-03-17 | 2011-01-05 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Vectors and methods for generating vector-free induced pluripotent stem (ips) cells using site-specific recombination |
| EP2103685A1 (en) | 2008-03-20 | 2009-09-23 | Helmholtz Zentrum München Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Vectors and methods for generating vector-free induced pluripotent stem (iPS) cells using site-specific recombination |
| CN101302553A (zh) | 2008-05-30 | 2008-11-12 | 广州华峰生物科技有限公司 | 基于环介导等温扩增技术的结核分歧杆菌基因快速诊断试剂盒及其检测方法 |
| WO2009152529A2 (en) | 2008-06-13 | 2009-12-17 | Whitehead Institute For Biomedical Research Nine Cambridge Center | Programming and reprogramming of cells |
| WO2010008054A1 (ja) | 2008-07-16 | 2010-01-21 | ディナベック株式会社 | 染色体非組み込み型ウイルスベクターを用いてリプログラムされた細胞を製造する方法 |
| WO2010019569A1 (en) | 2008-08-12 | 2010-02-18 | Cellular Dynamics International. Inc. | Methods for the production of ips cells |
| WO2010030003A1 (ja) | 2008-09-12 | 2010-03-18 | 協和発酵キリン株式会社 | 細胞のリプログラミングに用いられる複数遺伝子の発現制御システム |
| EP2191840A1 (en) | 2008-11-28 | 2010-06-02 | Sanofi-Aventis | Antitumor combinations containing antibodies recognizing specifically CD38 and melphalan |
| CA2688804A1 (en) | 2008-12-17 | 2010-06-17 | The Uab Research Foundation | Polycistronic vector for human induced pluripotent stem cell production |
| CA2748009A1 (en) | 2008-12-23 | 2010-07-01 | Vivoscript, Inc. | Compositions and methods for re-programming cells without genetic modification |
| WO2010104357A2 (ko) | 2009-03-12 | 2010-09-16 | 주식회사 프로셀제약 | 환자맞춤형 줄기세포치료를 위한 세포투과성 역분화 전사인자를 이용한 유도만능줄기세포 확립 |
| US20120128655A1 (en) | 2009-04-03 | 2012-05-24 | The Mclean Hospital Corporation | Induced pluripotent stem cells |
| US10837020B2 (en) | 2009-04-22 | 2020-11-17 | Massachusetts Institute Of Technology | Innate immune suppression enables repeated delivery of long RNA molecules |
| WO2010123501A1 (en) | 2009-04-22 | 2010-10-28 | Massachusetts Institute Of Technology | Innate immune suppression enables repeated delivery of long rna molecules |
| DK2432881T3 (en) | 2009-05-18 | 2018-02-26 | Curna Inc | TREATMENT OF REPROGRAMMING FACTOR-RELATED DISEASES BY INHIBITING NATURAL ANTISENSE TRANSCRIPTS TO A REPROGRAMMING FACTOR |
| US8734809B2 (en) | 2009-05-28 | 2014-05-27 | University Of Massachusetts | AAV's and uses thereof |
| CN101993495B (zh) | 2009-08-12 | 2013-07-24 | 上海近岸科技有限公司 | 一种蛋白质混合物及其制备方法 |
| WO2011024550A1 (ja) | 2009-08-31 | 2011-03-03 | 国立大学法人大阪大学 | 口腔粘膜由来細胞を利用した誘導多能性幹細胞の効率的な製造方法 |
| WO2011034421A1 (en) | 2009-09-16 | 2011-03-24 | Stichting Het Nederlands Kanker Instituut | Fra-1 target genes as drug targets for treating cancer |
| US8326547B2 (en) | 2009-10-07 | 2012-12-04 | Nanjingjinsirui Science & Technology Biology Corp. | Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm |
| WO2011130624A2 (en) | 2010-04-16 | 2011-10-20 | Immune Disease Institute, Inc. | Sustained polypeptide expression from synthetic, modified rnas and uses thereof |
| WO2011145615A1 (ja) | 2010-05-18 | 2011-11-24 | タカラバイオ株式会社 | 多能性幹細胞の製造のための核酸 |
| EP2388336A1 (en) | 2010-05-19 | 2011-11-23 | Signature Diagnostics AG | Method and kits for diagnosing colorectal cancer |
| US9580689B2 (en) | 2010-07-22 | 2017-02-28 | Regents Of The University Of Minnesota | Induced pluripotent stem cells |
| JP2013535966A (ja) | 2010-07-27 | 2013-09-19 | テクニオン リサーチ アンド ディベロップメント ファウンデーション リミテッド | 引き抜かれた毛包由来のケラチン生成細胞から誘導多能性幹細胞を生成させる方法 |
| US9090909B2 (en) | 2010-08-30 | 2015-07-28 | Dnavec Corporation | Composition for inducing pluripotent stem cell, and use thereof |
| EP3702460A1 (en) | 2010-11-12 | 2020-09-02 | The General Hospital Corporation | Polycomb-associated non-coding rnas |
| AU2011349464B2 (en) | 2010-12-20 | 2016-07-07 | The General Hospital Corporation | Polycomb-associated non-coding RNAS |
| US9228204B2 (en) | 2011-02-14 | 2016-01-05 | University Of Utah Research Foundation | Constructs for making induced pluripotent stem cells |
| WO2012112603A1 (en) | 2011-02-14 | 2012-08-23 | University Of Utah Research Foundations | Constructs and methods for generating induced pluri potent stem ( ips) cells |
| DE102011005235B4 (de) | 2011-03-08 | 2017-05-24 | Sirs-Lab Gmbh | Verfahren zum Identifizieren einer Teilmenge von Polynucleotiden aus einer dem Humangenom entsprechenden Ausgangsmenge von Polynucleotiden zur in vitro Bestimmung eines Schweregrads der Wirtsantwort eines Patienten |
| WO2012136841A1 (en) | 2011-04-08 | 2012-10-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for rejuvenating cells |
| EP2710130B1 (en) | 2011-05-19 | 2022-06-29 | Fundación Pública Andaluza Progreso Y Salud | Highly inducible dual-promoter lentiviral tet-on system |
| GB201118964D0 (en) | 2011-11-03 | 2011-12-14 | Ucl Business Plc | Method |
| EP2828381A1 (en) | 2012-03-21 | 2015-01-28 | Rheinische Friedrich-Wilhelms-Universität Bonn | Induced neural stem cells |
| CA2869333A1 (en) | 2012-04-11 | 2013-10-17 | The Lubrizol Corporation | Dispersants derived from hydroxy fatty acid polyesters and polyalkylene glycol dispersants |
| AU2013266496B2 (en) | 2012-05-21 | 2018-08-09 | The Regents Of The University Of California | Generation of human iPS cells by a synthetic self- replicative RNA |
| WO2013177228A1 (en) | 2012-05-22 | 2013-11-28 | Loma Linda University | Generation of integration/transgene-free stem cells |
| EP2669381A1 (en) | 2012-05-30 | 2013-12-04 | AmVac AG | Method for expression of heterologous proteins using a recombinant negative-strand RNA virus vector comprising a mutated P protein |
| CN102816793B (zh) * | 2012-08-22 | 2014-09-10 | 陕西师范大学 | 单载体双向启动的Tet-on诱导表达系统及其构建方法和应用 |
| EP2898076B1 (en) * | 2012-09-19 | 2018-03-07 | DSM IP Assets B.V. | Cell modification method using essential genes as markers and optionally recycling these |
| EP2904103B8 (en) | 2012-10-01 | 2020-03-11 | Taipei Veterans General Hospital | Method for preparing induced pluripotent stem cells and its applications |
| US20150267174A1 (en) | 2012-10-09 | 2015-09-24 | Nakanobu Hayashi | Reprogramming peptide and use thereof |
| EP2922866B1 (en) | 2012-11-21 | 2019-01-23 | Merz Pharma GmbH & Co. KGaA | Means and methods for determination of botulinum neurotoxin biological activity |
| WO2014093574A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified polynucleotides for altering cell phenotype |
| CA2903359A1 (en) | 2013-05-27 | 2014-12-04 | Fraunhofer-Gesellschaft Zur Foerderung Der Angewandten Forschung E.V. | Targeted modulation of macrophages |
| KR102113829B1 (ko) | 2013-10-25 | 2020-05-25 | 웨인 스테이트 유니버시티 | 단백질-유도 생체내 세포 재프로그래밍을 통한 세포 전환 방법, 시스템 및 조성물 |
| WO2015077498A1 (en) | 2013-11-20 | 2015-05-28 | The University Of North Carolina At Chapel Hill | Methods and compositions for treating disorders of the eye |
| CN120536341A (zh) | 2014-03-04 | 2025-08-26 | 菲特治疗公司 | 改良的重编程方法和细胞培养平台 |
| US11339437B2 (en) | 2014-03-10 | 2022-05-24 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
| US20180363070A9 (en) | 2014-08-12 | 2018-12-20 | Univ Wayne State | Systems and methods to detect stem cell stress and uses thereof |
| KR101663811B1 (ko) | 2015-04-20 | 2016-10-11 | 연세대학교 산학협력단 | 뇌신경 질환의 예방 또는 치료용 약제학적 조성물 |
| EP3286318A2 (en) | 2015-04-22 | 2018-02-28 | Mina Therapeutics Limited | Sarna compositions and methods of use |
| US10428307B2 (en) | 2015-04-29 | 2019-10-01 | The Catholic University Of Korea Industry-Academic Cooperation Foundation | Method for converting mesenchymal stem cells into endothelial cells by using specific transcription factors |
| US11219636B2 (en) * | 2015-05-17 | 2022-01-11 | The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center | Compositions and methods for treating cancer |
| WO2017026776A1 (en) | 2015-08-10 | 2017-02-16 | Cellivery Therapeutics, Inc. | Improved cell-permeable reprogramming factor (icp-rf) recombinant protein and use thereof |
| EP3344294A4 (en) * | 2015-08-31 | 2019-03-20 | The Trustees Of The University Of Pennsylvania | CHIMERIC AAV ANTI-VEGF FOR THE TREATMENT OF CANCER IN DOGS |
| US11007213B2 (en) | 2016-04-01 | 2021-05-18 | University Of Iowa Research Foundation | Metabolically stabilized double stranded mRNA |
| WO2017180587A2 (en) | 2016-04-11 | 2017-10-19 | Obsidian Therapeutics, Inc. | Regulated biocircuit systems |
| WO2017191274A2 (en) | 2016-05-04 | 2017-11-09 | Curevac Ag | Rna encoding a therapeutic protein |
| WO2018041959A1 (en) | 2016-09-02 | 2018-03-08 | Ruprecht-Karls-Universität Heidelberg | Gene panel specific for pulmonary hypertension and its uses |
| JP7215994B2 (ja) | 2016-09-06 | 2023-01-31 | ザ チルドレンズ メディカル センター コーポレーション | 人工多能性幹細胞由来の免疫細胞 |
| EP3385373A1 (en) | 2017-04-05 | 2018-10-10 | Centro de Neurociências e Biologia Celular | Compositions for reprogramming cells into dendritic cells or antigen presenting cells, methods and uses thereof |
| US11339405B2 (en) | 2017-04-12 | 2022-05-24 | Academia Sinica | Kit and method for producing induced embryonic neural progenitors |
| US20210254056A1 (en) | 2017-05-05 | 2021-08-19 | Camp4 Therapeutics Corporation | Identification and targeted modulation of gene signaling networks |
| EP3658573A1 (en) * | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
| US12291717B2 (en) | 2017-09-13 | 2025-05-06 | Biontech Rna Pharmaceuticals Gmbh | RNA replicon for reprogramming somatic cells |
| CN111556751B (zh) | 2017-11-10 | 2024-07-12 | 霍华休斯医学研究院 | 经修饰的配体门控的离子通道及使用方法 |
| WO2019099552A1 (en) * | 2017-11-14 | 2019-05-23 | The J. David Gladstone Institutes | Methods of generating retinal pigment epithelium (rpe) |
| US11058729B2 (en) | 2018-01-25 | 2021-07-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Exosomes and miRNA to treat glaucoma |
| US11692029B2 (en) | 2018-03-05 | 2023-07-04 | The Schepens Eye Research Institute, Inc. | Therapy for glaucoma and optic neuropathy by targeting colony stimulating factors |
| AU2019300431A1 (en) | 2018-07-13 | 2021-01-14 | Ucl Business Ltd | Glucocerebrosidase gene therapy |
| WO2020069373A1 (en) | 2018-09-28 | 2020-04-02 | President And Fellows Of Harvard College | Cellular reprogramming to reverse aging and promote organ and tissue regeneration |
| US12274733B2 (en) | 2018-09-28 | 2025-04-15 | President And Fellows Of Harvard College | Cellular reprogramming to reverse aging and promote organ and tissue regeneration |
| WO2020069339A1 (en) | 2018-09-28 | 2020-04-02 | President And Fellows Of Harvard College | Mutant reverse tetracycline transactivators for expression of genes |
| WO2021183825A1 (en) | 2020-03-12 | 2021-09-16 | California Institute Of Technology | Adeno-associated viral capsids with expanded sizes |
| AU2021236391A1 (en) | 2020-03-13 | 2022-09-29 | Capricor, Inc. | Exosomal nucleic acid vaccine modularly configured to harness multiple antigen presentation mechanisms |
| US20210324414A1 (en) | 2020-04-16 | 2021-10-21 | Massachusetts Institute Of Technology | Compositions and methods for sequestering viruses |
| AU2022266615A1 (en) | 2021-04-27 | 2023-11-09 | The General Hospital Corporation | Aav capsids and uses thereof |
| US20240325568A1 (en) | 2021-07-20 | 2024-10-03 | The Broad Institute, Inc. | Engineered targeting compositions for endothelial cells of the central nervous system vasculature and methods of use thereof |
| WO2023196851A1 (en) | 2022-04-06 | 2023-10-12 | President And Fellows Of Harvard College | Reversing aging of the central nervous system |
-
2019
- 2019-09-27 WO PCT/US2019/053492 patent/WO2020069339A1/en not_active Ceased
- 2019-09-27 CA CA3113470A patent/CA3113470A1/en active Pending
- 2019-09-27 JP JP2021517702A patent/JP7589997B2/ja active Active
- 2019-09-27 EP EP19787521.4A patent/EP3856260A1/en active Pending
- 2019-09-27 US US17/280,294 patent/US12624362B2/en active Active
- 2019-09-27 CN CN201980076921.7A patent/CN113164625B/zh active Active
-
2026
- 2026-04-09 US US19/642,752 patent/US20260218208A1/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2014500022A (ja) | 2010-11-24 | 2014-01-09 | クロンテック・ラボラトリーズ・インコーポレーテッド | 分散型タンパク質形質導入ドメインを含む誘導性発現系転写モジュレータおよびその使用方法 |
| WO2014152607A2 (en) | 2013-03-14 | 2014-09-25 | University Of Massachusetts | Dosage compensating transgenes and cells |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3856260A1 (en) | 2021-08-04 |
| JP2022501060A (ja) | 2022-01-06 |
| CN113164625B (zh) | 2026-04-14 |
| CN113164625A (zh) | 2021-07-23 |
| WO2020069339A8 (en) | 2020-05-07 |
| CA3113470A1 (en) | 2020-04-02 |
| WO2020069339A1 (en) | 2020-04-02 |
| US20260218208A1 (en) | 2026-07-30 |
| US20210403923A1 (en) | 2021-12-30 |
| US12624362B2 (en) | 2026-05-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12624362B2 (en) | Mutant reverse tetracycline transactivators for expression of genes | |
| US12582698B2 (en) | Cellular reprogramming to reverse aging and promote organ and tissue regeneration | |
| US12274733B2 (en) | Cellular reprogramming to reverse aging and promote organ and tissue regeneration | |
| US20180230489A1 (en) | Regulatable expression using adeno-associated virus (aav) | |
| US20250325628A1 (en) | Reversing aging of the central nervous system | |
| US20240042058A1 (en) | Tissue-specific methods and compositions for modulating a genome | |
| US20250109398A1 (en) | Compositions for treating neurological disease | |
| US20230143758A1 (en) | Regulatory nucleic acid sequences | |
| US20250009906A1 (en) | Nociceptor-specific gene regulatory elements for the treatment of pain | |
| Rossi et al. | Transfection of Cultured Primary Neurons | |
| HK40088903A (en) | Regulatory nucleic acid sequences | |
| HK40100119A (en) | Methods for treating neurological disease |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220927 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220927 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230728 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231017 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20231213 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240129 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20240312 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240612 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20240813 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240912 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20241022 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20241107 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7589997 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |